- Supports the development of innovative vaccine candidates by licensing recombinant proteins and it's GLA-SE adjuvant formulation for R&D and upcoming clinical trials.
The kiss of the triatomine bug spreads the vector-borne parasitic disease, as people sleep soundly through the night all over Latin America.
People exposed to the life-threatening parasite, Trypanosoma cruzi, suffer chronic heart, digestive, and neurological conditions.
Only 50% of people infected with T. Cruzi develop skin lesions, indicating they have Chagas disease and should get treatment.
The parasite circulates the blood to the heart and digestive muscles, where they can live for decades, destructing the nervous system and heart muscles if left untreated.
A TREATABLE DISEASE
Treatment for Chagas disease is the antibiotic benznidazole or nifurtimox. It is most effective if taken within two months of being bit, during the 'acute' phase of disease. The longer one waits to take drug, whether due to latent infection or inability to access the treatment, the less effective the treatment is.
Insecticide sprays and house cleaning can deter or kill the triatomine bugs, but there is no protection against the disease otherwise. Blood screenings are important to identify latent cases to treat existing infection.
Chagas disease primarily affects Latin American countires, where the parasite is mostly transmitted to humans through contact with faeces or urine of the kissing bug. 21 countries in Latin America declare Chagas disease as endemic.
Rural communities used to be most burdened by disease but as populations mhave migrated, urban areas have reported infection detected in the United States of America, Canada, and many European countries.
AAHI is collaborating to support the development of a Chagas vaccine candidate that combines a recombinant T. cruzi protein, Tc24-C4, with AAHI's GLA-SE adjuvant formulation. The vaccine candidate is expected to enter human clinical trials in 2023.
The World Health Organization's goal is to eliminate transmission of Chagas disease in fifteen of the forty-one currently affected countries by 2030. AAHI's work is in alignment with this goal.